Home » Trials » SLCTR/2023/002
A Phase II/III randomized, controlled, open labelled study to evaluate the safety and efficacy of snake venom antiserum – Sri Lanka (SL-AVS) developed for Sri Lankan species vs currently used anti snake venom.
-
SLCTR Registration Number
SLCTR/2023/002
Date of Registration
The date of last modification
Mar 02, 2023
Scientific Title of Trial
A Phase II/III randomized, controlled, open labelled study to evaluate the safety and efficacy of snake venom antiserum – Sri Lanka (SL-AVS) developed for Sri Lankan species vs currently used anti snake venom.
Public Title of Trial
Open labelled study to evaluate the safety and efficacy of snake venom antiserum – Sri Lanka (SL-AVS) developed for Sri Lankan species vs currently used anti snake venom in patients with patients with snake bite.
Disease or Health Condition(s) Studied
Snakebite envenomation
Scientific Acronym
None
Public Acronym
None
Brief title
A Sri Lankan antivenom trial
Universal Trial Number
U1111-1287-6071
Any other number(s) assigned to the trial and issuing authority
2022/EC/29 (University of Peradeniya)
What is the research question being addressed?
Is a new Sri Lankan antivenom (SL-AVS) developed for Sri Lankan species safe and efficacious compared to the currently used anti snake venom in patients with snakebite?
Type of study
Interventional
Study design
Allocation
Randomized controlled trial
Masking
Single blinded : Participants, Data analysts
Control
Standard therapy/practice
Assignment
Parallel
Purpose
Treatment
Study Phase
Phase 2-3
Intervention(s) planned
The study will be conducted in Medical wards of 3 selected centers in Sri Lanka- TH Anuradhapura, TH- Rathnapura, BH- Kilinochch At first, about 20 patients with snakebite eligible to receive ASV will be randomized for a safety study of the candidate ASV. Having established the safety, the study will enroll a further 40 patients. Patients who attend the hospital emergency and are clinically eligible to receive ASV will be stabilized and then administered ASV intravenously. Investigations and management will be as per standard of care, till the discharge of the patient Method of randomization: block randomization (blocks of 4). Intervention- Snake Venom Antiserum, I.P. is a sterile solution containing enzyme refined anti snake venom equine immunoglobulin F(ab’)2 fragments for parenteral administration. Snake Venom Antiserum is supplied in 10 ml glass vial with 10 ml sterile water for injection, as diluent. The diluent will be withdrawn in to a 10 ml sterile syringe and the needle inserted through the vial stopper and injected to the powder. The contents will be mixed gently by a swirling action. The serum will be used as soon as possible after reconstitution. Administration is by slow IV infusion over one hour. The dose (number of vials used and frequency) will depend on envenomation. Comparator- ANTI-SNAKE VENOM SERUM, I.P. (ASVS).
Inclusion criteria
• Any patient of either sex, • Age between 18 and 60 years • Patients reporting with the history of confirmed snakebite, • SL-ASV will be administered only for systemic envenoming effects except local manifestations of confirmed cobra bites. The systemic envenoming effects are as follows: 1. Neurotoxic envenomation- Patients with ptosis, external ophthalmoplegia and respiratory failure 2. Haemotoxic envenomation- Patient presenting with bleeding manifestations with laboratory confirmation of coagulopathy such as WBCT >20 minutes (Whole Blood Clotting Test), elevated PT/INR and APTT. Local effects are as follows: 1. Patients presenting with local pain, swelling and necrosis following only for confirmed cobra bites. • Following are the criteria/indications for giving SL-ASV for hump- nosed viper bites 1 Patients with positive WBCT20 and or elevated PT/INR (VICC) . 2. Patients with oliguria/anuria (UOP < 0.5 mL/kg/hr for 6 hrs) or increased serum creatinine (> 27 µmol/L relative to a known base line value within 48 hrs/ or clinical diagnosis) [acute kidney injury]
Exclusion criteria
• Pre-existing renal disease, uncontrolled chronic obstructive airway disease, congestive heart failure and previous myocardial infarction • Patients taking diuretics, anticoagulants and antiplatelet drugs • Pregnant mothers
Primary outcome(s)
1.
Improvement in clinical criteria 1. Improvement of bleeding manifestations 2. Improvement of neurological manifestations (neck muscle power/improvement of ophthalmoplegia/ptosis) 3. Improvement of renal manifestations (urine output) 4. Improvement of local reaction |
[ Post AVS at 1 hour, 6 hours, 24 hours, and 48 hours. ] |
2.
Improvement in laboratory criteria: 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) 3. Improvement of renal abnormalities (Serum creatinine) 4. Improvement of inflammatory response (white cell count/C-reactive protein) |
[ Post AVS at 1 hour, 6 hours, 24 hours, and 48 hours. ] |
3.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[ Post AVS at 1 hour, 6 hours, 24 hours, and 48 hours ] |
4.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
5.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
6.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
7.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
8.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
9.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
10.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
11.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
12.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
13.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
14.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
15.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
16.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
17.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
18.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
19.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
20.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
21.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
22.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
23.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
24.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
25.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
26.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
27.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
28.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
29.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
30.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
31.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
32.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
33.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
34.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
35.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
36.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
37.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
38.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
39.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
40.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
41.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
42.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
43.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
44.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
45.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
46.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
47.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
48.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
49.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
50.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
51.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
52.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
53.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
54.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
55.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
56.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
57.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
58.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
59.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
60.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
61.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
62.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
63.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
64.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
65.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
66.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
67.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
68.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
69.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
70.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
71.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
72.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
73.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
74.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
75.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
76.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
77.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
78.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
79.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
80.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
81.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
82.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
83.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
84.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
85.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
86.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
87.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
88.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
89.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
90.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
91.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
92.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
93.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
94.
Improvement in laboratory criteria 1. Improvement and time taken for improvement of coagulopathy 2. Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) 3. Improvement of inflammatory response (white cell count/C-reactive protein). |
[] |
95.
Safety measures will be assessed by grade referred to the severity of the Adverse reactions. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to grade adverse reactions. |
[] |
Secondary outcome(s)
1.
Total dose of SL-ASV used to achieve clinical improvement |
[] |
2.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
3.
Total duration of hospital stay |
[] |
4.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
5.
Total duration of hospital stay. |
[] |
6.
Number of cases suffering complications of snakebite |
[] |
7.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
8.
Total duration of hospital stay. |
[] |
9.
Number of cases suffering complications of snakebite |
[] |
10.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
11.
Total duration of hospital stay. |
[] |
12.
Number of cases suffering complications of snakebite |
[] |
13.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
14.
Total duration of hospital stay. |
[] |
15.
Number of cases suffering complications of snakebite |
[] |
16.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
17.
Total duration of hospital stay. |
[] |
18.
Number of cases suffering complications of snakebite |
[] |
19.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
20.
Total duration of hospital stay. |
[] |
21.
Number of cases suffering complications of snakebite |
[] |
22.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
23.
Total duration of hospital stay. |
[] |
24.
Number of cases suffering complications of snakebite |
[] |
25.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
26.
Total duration of hospital stay. |
[] |
27.
Number of cases suffering complications of snakebite |
[] |
28.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
29.
Total duration of hospital stay. |
[] |
30.
Number of cases suffering complications of snakebite |
[] |
31.
Total time required for clinical recovery and discontinuation of SL-ASV |
[] |
32.
Total duration of hospital stay. |
[] |
33.
Number of cases suffering complications of snakebite |
[] |
Target number/sample size
Phase II- Intervention arm- 10 Comparator arm- 10 Phase III Intervention arm- 20 Comparator arm- 20
Countries of recruitment
Sri Lanka
Anticipated start date
2023-04-01
Anticipated end date
2024-04-01
Date of first enrollment
Date of study completion
Recruitment status
Pending
Funding source
George Steuart & Company
Regulatory approvals
Status
Approved
Date of Approval
2022-11-16
Approval number
2022/EC/29
Details of Ethics Review Committee
Name: | Ethics Review Committee, Faculty of Medicine, University of Peradeniya |
Institutional Address: | Faculty of Medicine, University of Peradeniya, Peradeniya. |
Telephone: | 081-2396361 |
Email: | chairpersonierc@gmail.com |
Contact person for Scientific Queries/Principal Investigator
S.A.M.Kularatne
Senior Professor of Medicine
Faculty of Medicine, University of Peradeniya, Peradeniya
0773420771
tbn1917@gmail.com
Contact Person for Public Queries
R.M.M.K.Namal Rathnayaka
Senior Lecturer
Department of Pharmacology, Faculty of Medicine, Sabaragamuwa University of Sri Lanka, Hidellana, Ratnapura, Sri Lanka.
0714337784
namal@med.sab.ac.lk
Do the investigators plan to share identified individual clinical trial participant-level data (IPD)?
No
IPD sharing plan description
Study protocol available
Yes
Protocol version and date
2022-11-02 version 2
Protocol URL
Results summary available
No
Date of posting results
Date of study completion
Final sample size
Date of first publication
Link to results
Brief summary of results